Back to Search Start Over

Transcatheter aortic valve replacement in patients with severe mitral or tricuspid regurgitation at extreme risk for surgery

Authors :
Stan Checuti
Stephen H. Little
Jeffrey J. Popma
Brijeshwar Maini
Tanvir Bajwa
Thomas G. Gleason
John Heiser
Stanley Katz
Alan R. Hartman
Mubashir Mumtaz
George Petrossian
Neal S. Kleiman
Newell Robinson
Michael J. Reardon
G. Michael Deeb
William Merhi
Steven J. Yakubov
David H. Adams
Shuzhen Li
Daniel O'Hair
B. Jane Moore
Source :
The Journal of Thoracic and Cardiovascular Surgery. 155:1991-1999
Publication Year :
2018
Publisher :
Elsevier BV, 2018.

Abstract

Objectives Patients with symptomatic severe aortic stenosis and severe mitral regurgitation or severe tricuspid regurgitation were excluded from the major transcatheter aortic valve replacement trials. We studied these 2 subgroups in patients at extreme risk for surgery in the prospective, nonrandomized, single-arm CoreValve US Expanded Use Study. Methods The primary end point was all-cause mortality or major stroke at 1 year. A favorable medical benefit was defined as a Kansas City Cardiomyopathy Questionnaire overall summary score greater than 45 at 6 months and greater than 60 at 1 year and with a less than 10-point decrease from baseline. Results There were 53 patients in each group. Baseline characteristics for the severe mitral regurgitation and severe tricuspid regurgitation cohorts were age 84.2 ± 6.4 years and 84.9 ± 6.5 years; male, 29 (54.7%) and 22 (41.5%), and mean Society of Thoracic Surgeons score 9.9% ± 5.0% and 9.2% ± 4.0%, respectively. Improvement in valve regurgitation from baseline to 1 year occurred in 72.7% of the patients with severe mitral regurgitation and in 61.8% of patients with severe tricuspid regurgitation. A favorable medical benefit occurred in 31 of 47 patients (66.0%) with severe mitral regurgitation and 33 of 47 patients (70.2%) with severe tricuspid regurgitation at 6 months, and in 25 of 44 patients (56.8%) with severe mitral regurgitation and 24 of 45 patients (53.3%) with severe tricuspid regurgitation at 1 year. All-cause mortality or major stroke for the severe mitral regurgitation and severe tricuspid regurgitation cohorts were 11.3% and 3.8% at 30 days and 21.0% and 19.2% at 1 year, respectively. There were no major strokes in either group at 1 year. Conclusions Transcatheter aortic valve replacement in patients with severe mitral regurgitation or severe tricuspid regurgitation is reasonable and safe and leads to improvement in atrioventricular valve regurgitation.

Details

ISSN :
00225223
Volume :
155
Database :
OpenAIRE
Journal :
The Journal of Thoracic and Cardiovascular Surgery
Accession number :
edsair.doi...........386a5aa25c8b21d4320bce31df6a7c2f